Key facts
- It has raised $1.3M across 1 recorded rounds; the latest was Seed Round ($1.1M) in Dec 2022.
- Flavocure Biotech has filed 2 Form Ds with the SEC since 2023, most recently Feb 2025 ($215K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Flavocure Biotech
Funding rounds
1 roundsAbout Flavocure Biotech
Operator of drug research and botanical product development company intended to provide cures for certain cancers. The company develops molecules and generates preliminary data indicating activity against therapeutically validated kinase mutation targets, enabling healthcare professionals to transform the medicinal properties of natural products into new cures for mankind.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2014
- Website
- flavocure.com/
- Ownership
- Privately Held (backing)
Flavocure Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Flavocure Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Flavocure Biotech in its N-PORT filings yet. We sweep new filings monthly.